Abstract 1558P
Background
The Gail model (GM) has proven to be a valuable tool for breast cancer risk assessment in the Western population. There is limited evidence regarding its accuracy and validity in MENA populations.
Methods
The study included women who attended a breast cancer screening program at Cairo University Hospitals from November 2019 till May 2021. GM calculates the risk compared to matched women of the same age from the USA population, a further independent screening cohort of 8400 British women aged > 50 years was used for cross-comparison. The USA-validated risk score cutoff of 1.67 was used to define high-risk women. GM clinical validity was evaluated using calibration measured by 5-year observed to expected cancer events ratio (O/E) and discrimination measured by the AUC of the ROC curve analysis.
Results
A total of 10604 women attended for screening and 175 (1.7%) were finally diagnosed with breast cancer. The median age of cases was significantly older compared to controls (53 vs 46 years, p<0.001). The mean 5-year risk and lifetime risk scores were 0.85 and 8.49, respectively. The mean 5-year-risk in cases vs controls was 1.18 vs. 0.84. The O/E ratio was 0.47 with a relative difference of -4.64%. The cutoff for high-risk showed a sensitivity of 18.3%, specificity of 91.4%, and AUC of 0.55 (p= 0.029) in our cohort. The cases had a significantly higher rate of high-risk women compared to controls (18.9% vs 8.6%, p< 0.0001). Compared to the USA women of matched age, our cohort had a significantly lower rate of high-risk women (9% vs 13.5%, p<0.0001). Limiting the analysis to women aged > 50 years, Egyptian women had less rate of high risk compared to the USA (21% vs 37%, p< 0.001) and British women (21% vs 47%, p<0.001). An age-adjusted logistic regression analysis identified other significant non-GM risk factors including body mass index (odds ratio (OR): 1.02, 95% CI: 1.00-1.03, p= 0.025) and mammographic density (OR: 1.50, 95%CI: 1.08- 2.10, p= 0.017).
Conclusions
GM showed a modest discriminatory power in identifying high-risk women in our cohort. In addition, GM overpredicted the risk of breast cancer occurrences. Breast cancer risk models validated in Western populations should be used cautiously in other populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cairo University.
Disclosure
K.S. Shohdy: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis; Financial Interests, Other, Educational Grant: Adaptimmune. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10